奥瑞克制药

最新新闻

• 公司公告
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2025/10/4
• 评级变动
  Wells Fargo Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)
  TipRanks · 2026/6/3
• 评级变动
  Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• 公司公告
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2026/1/7
• 评级变动
  HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
  Benzinga · 2026/6/8
• 公司公告
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
  SEC · 2026/1/7
• 评级变动
  Piper Sandler Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
  Benzinga · 2026/8/10
• 公司公告
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2026/10/3
• 评级变动
  Goldman Sachs Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Stifel Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/6/24
• J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• BTIG Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 公司公告
  Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
  SEC · 2026/1/21
• A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。